Skip to main content

LCD L34658: Vitamin D Assay Testing

LCD L34658, Vitamin D Assay Testing, is the Local Coverage Determination that Wisconsin Physicians Service Insurance Corporation applies to claims from 48 states (AK, AL, AR, AZ, CA, CO, CT, DE and others), effective 2025-08-28 and first in force 2015-10-01. The policy text runs 845 words, and its billing and coding article A57484 lists 882 ICD-10-CM codes that support medical necessity for 2 procedure codes. 4 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 882 covered ICD-10-CM codes: 329 more codes than L37535 (Wellpoint Federal, 553 codes, revised 2026-04-01) and 360 more codes than L39391 (Palmetto GBA, 522 codes, revised 2026-01-01).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wisconsin Physicians Service Insurance Corporation
States and territories
48
AK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY
Revision effective
2025-08-28
Original effective
2015-10-01
Policy text
845 words
Covered ICD-10 codes (articles)
882

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34658
ContractContractorTypeStates
05101Wisconsin Physicians Service Insurance CorporationMAC - Part AIA
05201Wisconsin Physicians Service Insurance CorporationMAC - Part AKS
05301Wisconsin Physicians Service Insurance CorporationMAC - Part AMO
05401Wisconsin Physicians Service Insurance CorporationMAC - Part ANE
05102Wisconsin Physicians Service Insurance CorporationMAC - Part BIA
05202Wisconsin Physicians Service Insurance CorporationMAC - Part BKS
05302Wisconsin Physicians Service Insurance CorporationMAC - Part BMO
05402Wisconsin Physicians Service Insurance CorporationMAC - Part BNE
08101Wisconsin Physicians Service Insurance CorporationMAC - Part AIN
08102Wisconsin Physicians Service Insurance CorporationMAC - Part BIN
08201Wisconsin Physicians Service Insurance CorporationMAC - Part AMI
08202Wisconsin Physicians Service Insurance CorporationMAC - Part BMI
05901Wisconsin Physicians Service Insurance CorporationMAC - Part AAK AL AR AZ CA CO CT DE FL GA HI IA ID IL IN KS KY LA MA MD ME MI MO MS MT NC ND NE NH NJ NM NV OH OK OR PA RI SC SD TN TX UT VA VT WA WI WV WY

Billing and coding article A57484: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A57484 (Billing and Coding: Vitamin D Assay Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A57484: Billing and Coding: Vitamin D Assay Testing (Billing and Coding, effective 2024-10-01)

Covered ICD-10-CM codes
882
2 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
2
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A57484
ICD-10-CMDescription (FY2027)
A15.0Tuberculosis of lung
A15.4Tuberculosis of intrathoracic lymph nodes
A15.5Tuberculosis of larynx, trachea and bronchus
A15.6Tuberculous pleurisy
A15.7Primary respiratory tuberculosis
A15.8Other respiratory tuberculosis
A17.0Tuberculous meningitis
A17.1Meningeal tuberculoma
A17.81Tuberculoma of brain and spinal cord
A17.82Tuberculous meningoencephalitis
A17.83Tuberculous neuritis
A17.89Other tuberculosis of nervous system
A17.9Tuberculosis of nervous system, unspecified
A18.01Tuberculosis of spine
A18.02Tuberculous arthritis of other joints
A18.03Tuberculosis of other bones
A18.09Other musculoskeletal tuberculosis
A18.10Tuberculosis of genitourinary system, unspecified
A18.11Tuberculosis of kidney and ureter
A18.12Tuberculosis of bladder
A18.13Tuberculosis of other urinary organs
A18.14Tuberculosis of prostate
A18.15Tuberculosis of other male genital organs
A18.16Tuberculosis of cervix

Procedure codes: 82306, 82652.

Coverage indications, limitations and medical necessity

Vitamin D is a hormone, synthesized by the skin, the liver, and then metabolized by the kidney to an active hormone, calcitriol. An excess of vitamin D may lead to hypercalcemia. Vitamin D deficiency may lead to a variety of disorders. This LCD identifies the indications and limitations of Medicare coverage and reimbursement for these services.

Vitamin D is called a "vitamin" because of its availability from an exogenous source, predominantly from oily fish in the form of cholecalciferol, vitamin D3. Plant-based vitamin D is in the form of ergocalciferol, Vitamin D2. It is really a hormone, as it is synthesized by the skin, metabolized by the liver, and converted by the kidney to an active hormone, calcitriol. Calcitriol in its classical action, absorbs calcium from the intestine, and promotes bone mineralization.

In the skin, 7-dehydrocholesterol is converted to vitamin D3 in response to sunlight, a process that is inhibited by sunscreen with a skin protection factor (SPF) of 8 or greater. Once in the blood, vitamin D2 or D3 from diet, or D3 from skin production are carried by an alpha-2-globulin, vitamin D binding protein, and are carried to the liver where they are hydroxylated to yield 25-hydroxyvitamin D (25OHD; calcidiol). 25OHD then is converted in the kidney to 1, 25(OH)2D (calcitriol) by the action of 25OHD-1-alpha hydroxylase (CYP27B1). The CYP27B1 in the kidney is regulated by nearly every hormone involved in calcium homeostasis, and its activity is stimulated by PTH, estrogen, calcitonin, prolactin, growth hormone, low calcium levels, and low phosphorus levels. Its activity is inhibited by calcitriol, thus providing the feedback loop that helps regulates its synthesis.

An excess of vitamin D is unusual, but may lead to hypercalcemia. Vitamin D deficiency may lead to a variety of disorders; the well-described is rickets in growing children or osteomalacia in adults. Evaluating the status of a patient’s vitamin D sufficiency is accomplished by measuring the level of 25-hydroxyvitamin D. Measurement of other metabolites is generally not necessary outside of several unusual metabolic bone disorders or in chronic kidney disease-mineral bone disorder (CKD-MBD).

Indications:

Measurement of vitamin D levels is indicated for patients with:

• chronic kidney disease stage III or greater;

• osteoporosis;

• osteomalacia;

• osteopenia;

• osteogenesis imperfecta;

• osteosclerosis;

• hypocalcemia;

• hypercalcemia;

• hypoparathyroidism;

• hyperparathyroidism;

• rickets;

• vitamin D deficiency to monitor the efficacy of replacement therapy;

• fibromyalgia;

• granuloma forming diseases;

• hypovitaminosis D;

• hypervitaminosis D;

• long term use of anticonvulsants or glucocorticoids and other medications known to lower - vitamin D levels;

• malabsorption states;

• obstructive jaundice;

• cirrhosis;

• psoriasis;

• Paget’s disease of bone;

• gastric bypass;

• obesity.

Limitations:

For Medicare beneficiaries, screening tests are governed by statute (Social Security Act 1861 {nn}). Vitamin D testing may not be used for routine screening.

Assays of calcitriol need not be performed for each of the above conditions. The most common type of vitamin D deficiency is that of 25 OH Vitamin D.

The 1,25-dihydroxy form of vitamin D is generally only required to assist in the diagnosis of certain cases of rare endocrine disorders (primary hyperparathyroidism, hypothyroidism, pseudohypoparathyroidism), or for diagnosing and treating renal osteodystrophy and vitamin D-dependent and vitamin D resistant rickets, or in cases of unknown causes of hypercalcemia, including sarcoidosis. Levels of both 25OHD and calcitriol are not needed as a panel for determining a patient's vitamin D status or to monitor routine vitamin D replacement therapy for most diseases. It is expected that the medical record will justify the tests chosen for a particular disease entity, that all available components of 25 OH vitamin D and other metabolite levels will not be performed routinely on every patient, and that supportive documentation for test choices will be available to the Contractor upon request.

This Contractor does not expect to receive billing for the various component sources of 25 OH vitamin D separately (such as stored D or diet derived D). Only 1 total 25 OH vitamin D assay (comprising the sum of both 25OHD2 and 25OHD3) will be considered for reimbursement on any particular day, if medically necessary, for the patient's condition.

Once a beneficiary has been shown to be vitamin D deficient, further testing may be medically necessary only to ensure adequate replacement has been accomplished for this vitamin deficiency, although, generally, other parameters are measured. Annual testing of vitamin D status may be appropriate depending upon the indication and other mitigating factors. Because there can be variability in individual 25OHD responses to supplemental vitamin D in high-risk individuals, the serum 25OHD levels could be retested after about 3 months of supplementation to confirm that the target 25OHD level has been reached. If the follow up test shows they have not yet reached the target level, the test can be repeated in another 3 months until the target level is achieved.

Testing Methods

Several methods are available for measuring circulating concentrations of 25-OH-D. Medicare will cover laboratory tests that give practitioners accurate and reliable information. The method used to perform this testing should be validated.

Summary of evidence (opening)

N/A

The contractor cites 8 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2025-08-28
Last reviewed by the contractor
2025-07-15
MCD version
36
Derived from
L31076

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wisconsin Physicians Service Insurance Corporation hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34658 cover?

Vitamin D is a hormone, synthesized by the skin, the liver, and then metabolized by the kidney to an active hormone, calcitriol. An excess of vitamin D may lead to hypercalcemia. Vitamin D deficiency may lead to a variety of disorders. This LCD identifies the indications and limitations of Medicare coverage and reimbursement for these services. The full 845-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34658 apply to?

Wisconsin Physicians Service Insurance Corporation applies it to Medicare claims in 48 states: AK, AL, AR, AZ, CA, CO, CT, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY. It binds only that contractor; 4 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34658?

The companion billing and coding article A57484 lists 882 ICD-10-CM codes in 2 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34658?

A denial under LCD L34658 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A57484's 882 covered diagnosis codes, then file a redetermination with Wisconsin Physicians Service Insurance Corporation within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.